GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
GYRE THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$6.09+0.01 (+0.16%)
Close on Oct 19, 2026
- Market cap
- $612.88M
- P/E (TTM)
- –
- Dividend yield
- –
GYRE THERAPEUTICS, INC. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gyre Pharmaceuticals | $29.10M | $22.52M | $37.20M | $30.56M | $26.77M | $22.06M | $27.87M | $25.49M | $25.23M | $27.17M | $27.15M | $32.04M | 100.0% | +8.7% |
| Gyre | $8.00K | $0 | – | – | $2.96M | $0 | – | – | – | – | – | – | 0.0% | -99.7% |
| Other Unallocated Amount | – | $0 | – | – | – | $0 | – | – | – | – | – | – | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gyre Pharmaceuticals | – | -$3.07M | $3.16M | $8.87M | $4.23M | $3.74M | $2.24M | $6.05M | $4.35M | $9.39M | -$497.00K | $12.76M | – |
| Gyre | – | -$6.28M | -$3.04M | -$1.93M | -$2.06M | -$1.46M | -$1.58M | -$1.82M | -$1.15M | -$1.31M | – | – | – |
| Other Unallocated Amount | – | -$6.00K | -$3.00K | -$11.00K | -$2.00K | -$3.00K | $4.00K | -$5.00K | -$1.00K | – | -$2.74M | $2.00K | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceutical Products | $29.10M | – | – | – | $26.80M | – | – | – | – | – | – | – | 100.0% | +8.6% |
| ETUARY | – | $22.50M | – | $30.60M | $26.80M | $22.10M | $27.86M | $25.50M | $25.20M | $27.20M | $27.15M | $32.00M | – | – |
By region
From the segment and revenue-disaggregation notes of Gyre Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.